Skip to main content
Delfa

← Trials/Trial dossier/NCT05006781

SuspendedPhase 2

The Dose Finding Study of DAOIB Added to tDCS for AD

The Dose Finding Study of Sodium Benzoate Added to tDCS for the Treatment of Early-phase Alzheimer's Disease

Asset

DAOIB

Listed sites

1

Recruiting sites

-

Enrollment

140

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 10-26

Primary endpoint

•The Alzheimer's disease assessment scale - cognitive subscale

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID202002208A0
NCT IDNCT05006781

Timeline

Milestones

Study first posted2021-08-16actual
Last update posted2026-03-20actual
Study start2027-01estimated (month precision)
Primary completion2028-12estimated (month precision)
Study completion2028-12estimated (month precision)

Assets

Drug assets

DAOIB

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
Maximum age100 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
•MMSE between 10-26
•CDR 1 or 0.5

Exclusion criteria

•Hachinski Ischemic Score > 4
•Substance abuse/dependence
•Parkinson disease, epilepsy, dementia with psychotic features
•Major depressive disorder
•Major physical illnesses
•Severe visual or hearing impairment

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Caregiver / quality of life
2
Global cognition
1
Memory
1
Function / daily living
1
Other (unclassified)
1

Global cognition

1 endpoint
Secondary/protocol endpoint

Change from baseline in Mini-Mental Status examination score at week 10, 18 and 26

Time frame:week 0, 10, 18, 26

Mini-Mental State Examination (MMSE)

change from baseline, improvement

Memory

1 endpoint
Secondary/protocol endpoint

Change from baseline in the composite score of a battery of additional cognitive tests at week 26

Time frame:week 0, 26

change from baseline, improvement

Function / daily living

1 endpoint
Secondary/protocol endpoint

Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 10, 18 and 26

Time frame:week 0, 10, 18, 26

change from baseline, improvement

Caregiver / quality of life

2 endpoints
Secondary/protocol endpoint

Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 10, 18 and 26

Time frame:week 10, 18, 26

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline in Quality of life score at week 10, 18 and 26

Time frame:week 0, 10, 18, 26

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 10, 18 and 26

Time frame:week 0, 10, 18, 26

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.